CARDIOGENIC SHOCK PAST PRESENT AND FUTURE CLINICAL TRIALS

Saturday, February 25, 2023

11:30 AM – 12:10 PM ET

Moderator(s)

Cara Hendry, MD FRCP LLM

Consultant Cardiologist
Manchester University NHS Foundation Trust
Bolton , England, United Kingdom

Disclosure(s): No financial relationships to disclose
Duane Pinto, MD, MPH, FSCAI

Chief Medical Officer
JenaValve
Boston, Massachusetts, United States

Disclosure(s): Abbott Vascular, Asahi, Boston Scientific, St Jude, Terumo: Consulting fees or other remuneration (Ongoing); Abiomed: Consultant (Ongoing), University Grants/Research Support (Ongoing); Biotronik: Consultant (Ongoing); BSC: Consultant (Ongoing), University Grants/Research Support (Ongoing); CSL Behring: Consultant (Ongoing), University Grants/Research Support (Ongoing); JenaValve Technology Inc: Employee (Ongoing); Magenta Medical: Consultant (Ongoing); Medtronic Inc: Consultant (Ongoing); NuPulse CV, Inc.: Stock-privately held company (Ongoing)

Disclosure(s):

Cara Hendry, MD FRCP LLM: No financial relationships to disclose

Duane Pinto, MD, MPH, FSCAI: Abbott Vascular, Asahi, Boston Scientific, St Jude, Terumo: Consulting fees or other remuneration (Ongoing); Abiomed: Consultant (Ongoing), University Grants/Research Support (Ongoing); Biotronik: Consultant (Ongoing); BSC: Consultant (Ongoing), University Grants/Research Support (Ongoing); CSL Behring: Consultant (Ongoing), University Grants/Research Support (Ongoing); JenaValve Technology Inc: Employee (Ongoing); Magenta Medical: Consultant (Ongoing); Medtronic Inc: Consultant (Ongoing); NuPulse CV, Inc.: Stock-privately held company (Ongoing)